Alitretinoin
A retinoid medication related to vitamin A that activates nuclear receptors to normalize skin cell growth and reduce inflammation, used to treat severe chronic hand eczema that has not responded to other treatments. It is also studied in certain skin cancers like Kaposi's sarcoma, where it helps regulate abnormal cell proliferation.
Peso molecular
300,4000 g/mol
LogP
6,30
TPSA
37,30 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1
InChI
InChI=1S/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8-,16-14+
Molecular Formula
C20H28O2
HBD / HBA
1 / 2
Enlaces Rotables
5
Átomos Pesados
22
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A retinoid medication related to vitamin A that activates nuclear receptors to normalize skin cell growth and reduce inflammation, used to treat severe chronic hand eczema that has not responded to other treatments. It is also studied in certain skin cancers like Kaposi's sarcoma, where it helps regulate abnormal cell proliferation.
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Yes, Alitretinoin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL705. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 449171. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="alitretinoin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/alitretinoin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/alitretinoin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/alitretinoin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="alitretinoin"></drugfyi-drug>